| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Departments of Pharmacology and Toxicology [G. B. J. S., T. E. M.], Surgery [K. R. R., D. P.], and Medicine [T. E. M.], and School of Environmental Studies [T. E. M.], Queen’s University, Kingston, Ontario K7L 3N6; Department of Pharmacology, University of Toronto, Toronto, Ontario M5S 1A8 [P. A. H., J. M. Y. W., M. S. M. L.]; and Division of Clinical Pharmacology and Toxicology, The Hospital for Sick Children, Toronto, Ontario M5G 1X8 [P. A. H.], Canada
There are numerous conflicting epidemiological studies addressing correlations between cytochrome P450 1A1 (CYP1A1) genetic polymorphisms and lung cancer susceptibility, with associations plausibly linked to alterations in carcinogen bioactivation. Similarly, correlations between aryl hydrocarbon receptor gene (AHR) codon 554 genotype and CYP1A1 inducibility are controversial. The objective of this study was to determine whether smoking status, and CYP1A1, AHR, and glutathione S-transferase M1 gene (GSTM1) polymorphisms correlate with altered CYP1A1 activities. Lung microsomal CYP1A1-catalyzed 7-ethoxyresorufin O-dealkylation (EROD) activities were much higher in tissues from current smokers (n = 46) than in those from non-/former smokers (n = 24; 12.11 ± 13.46 and 0.77 ± 1.74 pmol/min/mg protein, respectively, mean ± SD; P < 0.05). However, EROD activities in lung microsomes from current smokers CYP1A1*1/1 (n = 33) and heterozygous MspI variant CYP1A1*1/2A (n = 10) were not significantly different (12.23 ± 13.48 and 8.23 ± 9.76 pmol/min/mg protein, respectively, P > 0.05). Three current smokers were heterozygous variant CYP1A1*1/2B (possessing both *2A and *2C alleles), and exhibited activities similar to individuals CYP1A*1/1. One current smoker was heterozygous variant CYP1A1*4 and exhibited activities comparable with individuals CYP1A1*1/1 at that locus. EROD activities in microsomes from current smokers AHR554Arg/Arg (n = 41) and heterozygous variant AHR554Arg/Lys (n = 5) were not significantly different (12.13 ± 13.56 and 12.01 ± 14.23 pmol/min/mg protein, respectively; P > 0.05). Furthermore, microsomal EROD activities from current smokers with the GSTM1-null genotype (n = 28) were not significantly different from those (n = 18) carrying at least one copy of GSTM1 (12.61 ± 14.24 and 11.34 ± 12.53 pmol/min/mg protein, respectively; P > 0.05). Additionally, when genotypic combinations of CYP1A1, AHR, and GSTM1 were assessed, there were no significant effects on EROD activity. On the basis of microsomal enzyme activities from heterozygotes, CYP1A1*1/2A, CYP1A1*1/2B, CYP1A1*1/4, and AHR554 Arg/Lys variants do not appear to significantly affect CYP1A1 activities in human lung, and we observed no association between CYP1A1 activity and the GSTM1-null polymorphism.
This article has been cited by other articles:
|
|
 |
|
  C.-C. Ho, Y.-C. Ling, L. W. Chang, H.-T. Tsai, M.-H. Tsai, and P. Lin 17-Beta Estradiol and Hydroxyestradiols Interact via the NF-Kappa B Pathway to Elevate Cyclooxygenase 2 Expression and Prostaglandin E2 Secretion in Human Bronchial Epithelial Cells Toxicol. Sci., August 1, 2008; 104(2): 294 - 302. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. S. Hecht, P. W. Villalta, and J.B. Hochalter Analysis of phenanthrene diol epoxide mercapturic acid detoxification products in human urine: relevance to molecular epidemiology studies of glutathione S-transferase polymorphisms Carcinogenesis, May 1, 2008; 29(5): 937 - 943. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. B. Okey An Aryl Hydrocarbon Receptor Odyssey to the Shores of Toxicology: The Deichmann Lecture, International Congress of Toxicology-XI Toxicol. Sci., July 1, 2007; 98(1): 5 - 38. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. S. Hecht, S. G. Carmella, A. Yoder, M. Chen, Z.-z. Li, C. Le, R. Dayton, J. Jensen, and D. K. Hatsukami Comparison of polymorphisms in genes involved in polycyclic aromatic hydrocarbon metabolism with urinary phenanthrene metabolite ratios in smokers. Cancer Epidemiol. Biomarkers Prev., October 1, 2006; 15(10): 1805 - 1811. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. B. M. van Duursen, J. T. Sanderson, and M. van den Berg Cytochrome P450 1A1 and 1B1 in Human Blood Lymphocytes Are Not Suitable as Biomarkers of Exposure to Dioxin-like Compounds: Polymorphisms and Interindividual Variation in Expression and Inducibility Toxicol. Sci., May 1, 2005; 85(1): 703 - 712. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Georgiadis, J. Topinka, D. Vlachodimitropoulos, M. Stoikidou, M. Gioka, G. Stephanou, H. Autrup, N. A. Demopoulos, K. Katsouyanni, R. Sram, et al. Interactions between CYP1A1 polymorphisms and exposure to environmental tobacco smoke in the modulation of lymphocyte bulky DNA adducts and chromosomal aberrations Carcinogenesis, January 1, 2005; 26(1): 93 - 101. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Vassallo, S. M. Hicks, S. L. Born, and G. P. Daston Roles for Epoxidation and Detoxification of Coumarin in Determining Species Differences in Clara Cell Toxicity Toxicol. Sci., November 1, 2004; 82(1): 26 - 33. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A.-K. Alexandrie, F. Nyberg, M. Warholm, and A. Rannug Influence of CYP1A1, GSTM1, GSTT1, and NQO1 Genotypes and Cumulative Smoking Dose on Lung Cancer Risk in a Swedish Population Cancer Epidemiol. Biomarkers Prev., June 1, 2004; 13(6): 908 - 914. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Alexandrov, I. Cascorbi, M. Rojas, G. Bouvier, E. Kriek, and H. Bartsch CYP1A1 and GSTM1 genotypes affect benzo[a]pyrene DNA adducts in smokers' lung: comparison with aromatic/hydrophobic adduct formation Carcinogenesis, December 1, 2002; 23(12): 1969 - 1977. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Hunt, A. Strimas, J. E. Martin, M. Eyer, M. Haddican, B. G. Luckett, B. Ruiz, T. W. Axelrad, W. L. Backes, and E. T. H. Fontham Differences in KRAS Mutation Spectrum in Lung Cancer Cases between African Americans and Caucasians after Occupational or Environmental Exposure to Known Carcinogens Cancer Epidemiol. Biomarkers Prev., November 1, 2002; 11(11): 1405 - 1412. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. S. Hecht Human urinary carcinogen metabolites: biomarkers for investigating tobacco and cancer Carcinogenesis, June 1, 2002; 23(6): 907 - 922. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
